Biologics and conditions treated with biologics

(001) Advancements in Rheumatoid Arthritis Management: An Analysis of Clinical Features and Treatment Outcomes in a Brazilian Cohort

(002) Assessment of medication adherence and its factors influencing poor medication adherence among psoriasis patients: a cross-sectional study

(003) Assessment of medication adherence and the impact of clinical pharmacist interventions on medication adherence among systemic lupus erythematosus patients: a prospective cohort study

(004) Clinical and Economic Burden of Polymyalgia Rheumatica in Patients with an Inadequate Response to Glucocorticoids or Glucocorticoids Taper in a Real-World Setting

(005) Cohort studies on 71 different adverse health outcomes among people with atopic eczema in UK primary care data

(006) Determination of patients’ quality of life (QOL) and its influencing risk factors associated with QOL in patients with autoimmune systemic vasculitis: a cross-sectional study

(007) Determining lines of therapy in real world patients with rheumatoid arthritis: analyses of a nationwide claims database in Japan

(008) Disease Activity in Rheumatoid Arthritis Patients Initiating Anti-Obesity Medication in a Longitudinal US-Based Real-World Cohort

(009) Drug survival and safety of biosimilars compared with originator adalimumab for Psoriasis: a multinational cohort study

(011) Enhanced Pharmacovigilance to Contextualize 13 years of Monitoring: The Gilenya Pregnancy Registry put in Perspective with the Fingolimod PRegnancy outcomes Intensive Monitoring (PRIM) Program

(012) Ensuring Safety: A Comprehensive Review of the Subcutaneous Administration of Biologics

(013) Epidemiology and Disease Burden of Generalized Pustular Psoriasis – A Retrospective Cohort Study in Finland

(015) Estimating Prevalence of Moderate-to-Severe Systemic Lupus Erythematosus. A Literature Review

(016) Hormone Therapy and Risk of Psoriasis in Reproductive and Postmenopausal Women: A Nationwide Cohort Study in Taiwan

(018) Impact of Immune Checkpoint Inhibitors on Psoriasis Incidence: Emulation of a Randomized Target Trial Using Real-world Data

(019) Initial and subsequent biological therapies for patients with psoriasis vulgaris during 2010-2021 in Japan

(020) Initiation Trends of Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among Adults in the United States from 2001 to 2021

(021) Line of Therapy of Biologics and JAK Inhibitors in RA, PsA, and AxSpA: Implications for Design and Uptake of New Drugs and Diagnostics

(022) Market Uptake and Pattern of Use of Emerging Topical Rosacea Medications in Switzerland: a Descriptive Study using Swiss Claims Data

(023) Medication persistence in the treatment of rheumatoid arthritis in the Brazilian Public Health System

(024) Mortality in an Eosinophilic Granulomatosis with Polyangiitis (EGPA) Incident Cohort: A Retrospective Study in England

(025) Overall survival in immune checkpoint inhibitor-treated patients with rheumatoid arthritis and non-small cell lung cancer: a Medicare claims study

(026) Potential Drug Interaction in Janus Kinase Inhibitors Users Among Patients with Rheumatoid Arthritis or Psoriatic arthritis in Taiwan

(027) Prescribing Patterns of Biological Therapies in Psoriasis Management: A Retrospective Cohort Study in Saudi Arabia

(028) Prescription Patterns After the Approval of Dupilumab, Abrocitinib, Baricitinib, and Upadacitinib in Adults with Atopic Dermatitis: A Real-World Evidence from a Multi-Institutional Database in Taiwan

(029) Prevalence of dermatomyositis and polymyositis in adults and paediatric populations: a network cohort study part of DARWIN EU®

(030) Prevalence, characteristics, and prescription pain medication use in the rheumatoid arthritis population

(031) Real-World Patterns in Treatment Switching to Biosimilar Adalimumab in the United States

(032) Real-World Utilization Patterns of Immune Checkpoint Inhibitors: based on the National Health Insurance Service Data in Korea (2017-2022)

(033) Risk of hypertension and type 2 diabetes in patients with systemic lupus erythematous: A retrospective cohort study in Yinzhou, China

(034) Risk of safety outcomes associated with the long-term use of oral corticosteroids: A nested case-control study of 1 million patients with atopic dermatitis

(035) Safety Events in Patients with Polyarticular-Course Juvenile Idiopathic Arthritis Exposed to Tofacitinib (Xeljanz) or Biologics: Real-World Data from the CARRA Registry

(036) Serious Infection Risk Associated With Biologics and Systemic Nonbiologics in Patients With Psoriasis: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials

(038) Treatment of rheumatoid arthritis in the Brazilian Public Health System: medication use profile

(039) Treatment Patterns in Moderate to Severe Psoriasis: A Hospital-based Retrospective Analysis

(041) Use of Digital Health Tools to Evaluate Change in Clinical and Patient-Reported Outcomes Among Patients with Rheumatoid Arthritis Initiating Treatment with a JAKi or TNFi

(042) Use of Machine Learning to Evaluate Incremental Value of Actigraphy Data for Classifying Treatment Response in Patients with Rheumatoid Arthritis

(043) Utilization of newly approved targeted immunomodulating treatments for atopic dermatitis

(044) Utilizing Real-World Data to Create an External Control Arm for a Phase 3 Trial of Deucravacitinib for Treatment of Plaque Psoriasis

(045) Vitiligo Disease Severity and Real-World Treatment Patterns